Related Experiment Videos
Valproate monotherapy in 30 patients with partial seizures
1Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina 27103.
Epilepsia
|March 1, 1988
Summary
Valproate (VPA) effectively controlled or improved seizure activity in over 70% of patients with partial seizures who did not respond to other medications. VPA showed particular efficacy in patients experiencing generalized tonic-clonic seizures.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Epilepsy management often involves sequential antiepileptic drug (AED) trials.
- Patients with partial seizures (complex partial seizures [CPS] and simple partial seizures [SPS]) may fail or experience adverse reactions to first-line AEDs like carbamazepine (CBZ), phenytoin (PHT), or phenobarbital (PB).
Purpose of the Study:
- To evaluate the efficacy of valproate (VPA) monotherapy in patients with partial seizures refractory to or intolerant of other AEDs.
- To identify patient subgroups that may benefit most or least from VPA treatment.
Main Methods:
- Retrospective pilot study of 30 patients with CPS and/or SPS.
- Patients received VPA monotherapy after failing or reacting to CBZ, PHT, or PB.
- Seizure frequency was assessed for 90 days before VPA and 90 and 180 days after VPA initiation.
Main Results:
- Twenty-two of 30 patients (73.3%) showed a ≥51% reduction in seizure activity at 6 months.
- VPA was particularly effective in 17 patients with secondarily generalized tonic-clonic seizures (GTCS).
- Eight patients did not respond, possibly due to seizure type (SPS/CPS without GTCS) or seizure duration.
Conclusions:
- Valproate monotherapy is a viable treatment option for patients with partial seizures who have failed other AEDs.
- Further investigation, including a double-blind controlled trial, is warranted to confirm VPA's efficacy in partial seizures.